Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls (Q37810960)

23 August 2017

Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls (English)

1 reference

23 August 2017

0 references

0 references

0 references

Léia C R Silva

1

1 reference

PubMed ID

21091114

23 August 2017

Luciena C M Ortigosa

series ordinal

2

1 reference

PubMed ID

21091114

23 August 2017

Gil Benard

series ordinal

3

1 reference

23 August 2017

1 November 2010

1 reference

23 August 2017

1 reference

23 August 2017

2

1 reference

23 August 2017

6

1 reference

23 August 2017

817-833

1 reference

An endotoxin-induced serum factor that causes necrosis of tumors

23 August 2017

1 reference

The tumor necrosis factor ligand and receptor families.

21 January 2018

1 reference

Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments

21 January 2018

1 reference

Biological functions of tumor necrosis factor cytokines and their receptors

21 January 2018

1 reference

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

21 January 2018

1 reference

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

TNFalpha blockade in human diseases: mechanisms and future directions

21 January 2018

1 reference

Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report

21 January 2018

1 reference

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

21 January 2018

1 reference

Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease

21 January 2018

1 reference

Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study

21 January 2018

1 reference

Biology of tumor necrosis factor-alpha- implications for psoriasis

21 January 2018

1 reference

Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13.

21 January 2018

1 reference

Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis.

21 January 2018

1 reference

Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept

21 January 2018

1 reference

Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism

21 January 2018

1 reference

Atopic disorders in ankylosing spondylitis and rheumatoid arthritis

21 January 2018

1 reference

Effect of etanercept on matrix metalloproteinases and angiogenic vascular endothelial growth factor: a time kinetic study

21 January 2018

1 reference

Decreased levels of metalloproteinase-9 and angiogenic factors in skin lesions of patients with psoriatic arthritis after therapy with anti-TNF-alpha

21 January 2018

1 reference

Matrix metalloproteinases in tumour invasion and metastasis

21 January 2018

1 reference

Anti-cytokine therapy for rheumatoid arthritis

21 January 2018

1 reference

Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis

21 January 2018

1 reference

Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies.

21 January 2018

1 reference

Changing paradigms in dermatology: tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis

21 January 2018

1 reference

Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis

21 January 2018

1 reference

Natural regulatory T cells: mechanisms of suppression

21 January 2018

1 reference

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

TNF downmodulates the function of human CD4+CD25hi T-regulatory cells

21 January 2018

1 reference

Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy

21 January 2018

1 reference

Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta

21 January 2018

1 reference

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

21 January 2018

1 reference

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

21 January 2018

1 reference

Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans

21 January 2018

1 reference

Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system

21 January 2018

1 reference

Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells

21 January 2018

1 reference

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha

21 January 2018

1 reference

Guideline for anti-TNF-alpha therapy in psoriatic arthritis

21 January 2018

1 reference

Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease

21 January 2018

1 reference

Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis.

21 January 2018

1 reference

Fatal miliary Coccidioidomycosis in a patient receiving infliximab therapy: a case report

21 January 2018

1 reference

Infectious complications with anti-TNFalpha therapy in rheumatic diseases: a review

21 January 2018

1 reference

Sinusitis: a possible link with adalimumab.

21 January 2018

1 reference

Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients.

21 January 2018

1 reference

Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha

21 January 2018

1 reference

Possible miliary tuberculosis during adalimumab therapy with negative gamma-IFN release assays.

21 January 2018

1 reference

Tuberculous peritonitis after treatment with adalimumab

21 January 2018

1 reference

Olecranon bursitis secondary to Mycobacterium kansasii infection in a patient receiving infliximab for Behcet's disease.

21 January 2018

1 reference

Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy

21 January 2018

1 reference

Failure of isoniazid chemoprophylaxis during infliximab therapy

21 January 2018

1 reference

Oral histoplasmosis: an unusual presentation

21 January 2018

1 reference

Infliximab-induced disseminated histoplasmosis in a patient with Crohn's disease

21 January 2018

1 reference

Invasive mucormycosis of the maxillary sinus: extensive destruction with an indolent presentation

21 January 2018

1 reference

Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?

21 January 2018

1 reference

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

Septic shock after treatment of pyoderma gangrenosum with infliximab.

21 January 2018

1 reference

Fatal pneumococcal sepsis in patient with hidradenitis suppurative treated with infliximab

21 January 2018

1 reference

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

21 January 2018

1 reference

Herpes zoster infection followed by Henoch-Schönlein purpura in a girl receiving infliximab for ulcerative colitis.

21 January 2018

1 reference

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

21 January 2018

1 reference

Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease

21 January 2018

1 reference

The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature

21 January 2018

1 reference

Disseminated cutaneous Herpes Simplex Virus-1 in a woman with rheumatoid arthritis receiving infliximab: a case report

21 January 2018

1 reference

Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis

21 January 2018

1 reference

Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab

21 January 2018

1 reference

Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients.

21 January 2018

1 reference

Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium

21 January 2018

1 reference

Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands.

21 January 2018

1 reference

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update.

21 January 2018

1 reference

Leukemic phase of follicular lymphoma after treatment with etanercept in a patient with psoriasis.

21 January 2018

1 reference

Hypopigmented T-cell dyscrasia evolving to hypopigmented mycosis fungoides during etanercept therapy

21 January 2018

1 reference

A transient benign lymph node-based proliferation of T-cells simulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists

21 January 2018

1 reference

Update on medication-induced peripheral neuropathy

21 January 2018

1 reference

Adalimumab induced mononeuritis multiplex in a patient with refractory rheumatoid arthritis: a case report

21 January 2018

1 reference

Posterior reversible encephalopathy syndrome following infliximab infusion

21 January 2018

1 reference

Aseptic meningitis in a patient taking etanercept for rheumatoid arthritis: a case report

21 January 2018

1 reference

Lewis-Sumner syndrome associated with infliximab therapy in rheumatoid arthritis

21 January 2018

1 reference

Re: Complex regional pain syndrome after infliximab infusion.

21 January 2018

1 reference

Tumor necrosis factor-alpha antagonists and neuropathy

21 January 2018

1 reference

Multiple sclerosis following etanercept treatment for ankylosing spondylitis

21 January 2018

1 reference

Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha?

21 January 2018

1 reference

First case report of adalimumab-induced psoriasis in Crohn's disease.

21 January 2018

1 reference

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

21 January 2018

1 reference

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action

21 January 2018

1 reference

Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors

21 January 2018

1 reference

Digital vasculitis: a late complication of anti-tumour necrosis factor alpha therapy.

21 January 2018

1 reference

Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody

21 January 2018

1 reference

Pericarditis as a complication of infliximab therapy in Crohn's disease.

21 January 2018

1 reference

Retinal vein thrombosis following infliximab treatment for severe left-sided ulcerative colitis.

21 January 2018

1 reference

Overview of biologic therapy for Crohn's disease

21 January 2018

1 reference

Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease

21 January 2018

1 reference

Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab

21 January 2018

1 reference

Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.10.67

1 reference

23 August 2017

1 reference

PubMed ID

21091114